Ségolène Duran

1.3k total citations
15 papers, 1.1k citations indexed

About

Ségolène Duran is a scholar working on Infectious Diseases, Oncology and Virology. According to data from OpenAlex, Ségolène Duran has authored 15 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 5 papers in Oncology and 4 papers in Virology. Recurrent topics in Ségolène Duran's work include HIV/AIDS Research and Interventions (8 papers), HIV/AIDS drug development and treatment (7 papers) and HIV Research and Treatment (4 papers). Ségolène Duran is often cited by papers focused on HIV/AIDS Research and Interventions (8 papers), HIV/AIDS drug development and treatment (7 papers) and HIV Research and Treatment (4 papers). Ségolène Duran collaborates with scholars based in France, Vietnam and Mali. Ségolène Duran's co-authors include Bruno Spire, François Raffi, Catherine Leport, Jean‐Paul Moatti, Valérie Cailleton, Jean-Paul Moatti, Marc Souville, Patrizia Carrieri, Dominique Salmon‐Céron and Marianne Savès and has published in prestigious journals such as Blood, Clinical Infectious Diseases and Social Science & Medicine.

In The Last Decade

Ségolène Duran

15 papers receiving 1.1k citations

Peers

Countries citing papers authored by Ségolène Duran

Since Specialization

Citations

This map shows the geographic impact of Ségolène Duran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ségolène Duran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ségolène Duran more than expected).

Fields of papers citing papers by Ségolène Duran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ségolène Duran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ségolène Duran. The network helps show where Ségolène Duran may publish in the future.

Co-authorship network of co-authors of Ségolène Duran

This figure shows the co-authorship network connecting the top 25 collaborators of Ségolène Duran. A scholar is included among the top collaborators of Ségolène Duran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ségolène Duran. Ségolène Duran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017 2021 ·European Journal of Cancer ·Marc A. Rodwin, Julien Mancini, Ségolène Duran, (unknown), Patrice Viens, D Maraninchi, Anthony Gonçalvès, Patricia Marino	10
2	Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer 2018 ·Journal of Geriatric Oncology ·Renaud Sabatier, (unknown), (unknown), A.‐P. Jonville‐Béra, Anne Madroszyk, (unknown), (unknown), Ségolène Duran, (unknown), Franck Rouby, Joëlle Micallef, Frédérique Rousseau	17
3	Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma 2013 ·Hematological Oncology ·Sylvain Garciaz, Diane Coso, Frédéric Peyrade, Sabine Fürst, Ségolène Duran, Bruno Chetaille, I. Brenot-Rossi, Raynier Devillier, Angéla Granata, Didier Blaise, Réda Bouabdallah	39
4	De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study 2013 ·Intensive Care Medicine ·Djamel Mokart, (unknown), Jérôme Lambert, Antoine Sannini, Laurent Chow‐Chine, J.P. Brun, Pierre Berger, Ségolène Duran, Marion Faucher, J.L. Blache, Colombe Saillard, Norbert Vey, Marc Léone	86
5	Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma 2012 ·Experimental Hematology ·Jean El Cheikh, Roberto Crocchiolo, Sabine Fürst, Patrick Ladaique, Luca Castagna, Catherine Faucher, Angéla Granata, Claire Oudin, Claude Lemarié, Boris Calmels, Anne-Marie Stoppa, Jean‐Marc Schiano de Colella, Ségolène Duran, Christian Chabannon, Didier Blaise	31
6	Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation 2010 ·Hematology/Oncology and Stem Cell Therapy ·Jean El Cheikh, Luca Castagna, Ling Wang, Benjamin Esterni, Catherine Faucher, Sabine Fürst, Ségolène Duran, Pierre Berger, Stéphane Ranque, Mohamad Mohty, Didier Blaise	17
7	Features and Risk Factors of Peripheral Neuropathy during Treatment of Advanced Multiple Myeloma with Bortezomib. 2006 ·Blood ·Jean El Cheikh, Anne Marie Stoppa, Ségolène Duran, Réda Bouabdallah, Norbert Vey, Diane Coso, (unknown), Aude Charbonnier, Catherine Faucher, (unknown), Jacques Camerlo, Jean‐Albert Gastaut, Didier Blaise, Mohamad Mohty	2
8	The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination 2003 ·AIDS ·Ségolène Duran, Gilles Peytavin, Patrizia Carrieri, François Raffi, Jean-Luc Ecobichon, Edwige Pereira, (unknown), Bruno Spire, Catherine Leport	17
9	Health-Related Quality of Life After 1 Year of Highly Active Antiretroviral Therapy 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Patrizia Carrieri, Bruno Spire, Ségolène Duran, Christine Katlama, D. Peyramond, (unknown), Geneviève Chêne, Jean-Marie Lang, Jean‐Paul Moatti, Catherine Leport	111
10	Impact of Discontinuation of Initial Protease Inhibitor Therapy on Further Virological Response in a Cohort of Human Immunodeficiency Virus–Infected Patients 2002 ·Clinical Infectious Diseases ·Vincent Le Moing, Geneviève Chêne, Catherine Leport, Charlotte Lewden, Ségolène Duran, Michel Garré, Bernard Masquelier, M. Dupon, François Raffi, (unknown)	25
11	Mechanisms of Early Virologic Failure in Antiretroviral‐Naive Patients Starting Protease Inhibitor–Containing Regimens: The APROVIR Study 2002 ·The Journal of Infectious Diseases ·Bernard Masquelier, Gilles Peytavin, Catherine Leport, (unknown), Ségolène Duran, Renaud Verdon, Jean‐Marc Besnier, Geneviève Chêne, François Raffi, Françoise Brun‐Vézinet, (unknown)	22
12	Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach 2002 ·Social Science & Medicine ·Bruno Spire, Ségolène Duran, Marc Souville, Catherine Leport, François Raffi, Jean‐Paul Moatti	261
13	Self-Reported Symptoms After Initiation of a Protease Inhibitor in HIV-Infected Patients and Their Impact on Adherence to HAART 2001 ·HIV Clinical Trials ·Ségolène Duran, Bruno Spire, François Raffi, (unknown), Damien Bouhour, Valérie Journot, Valérie Cailleton, (unknown), Jean-Paul Moatti, (unknown)	193
14	‘Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?’ A comparison between patients’ self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study 2001 ·AIDS ·Ségolène Duran, Caroline Solas, Bruno Spire, Patrizia Carrieri, J.G. Fuzibet, Dominique Costagliola, Bruno Lacarelle, (unknown)	34
15	Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy 2001 ·AIDS ·Ségolène Duran, Marianne Savès, Bruno Spire, Valérie Cailleton, A Sobel, Patrizia Carrieri, Dominique Salmon‐Céron, Jean-Paul Moatti, (unknown)	233

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact